General Proximity, a San Francisco, CA-based biotech platform company, raised $16M in funding.
The round was led by Aydin Senkut at Felicis. Other investors included Y Combinator, age1, Modi Ventures, Wilson Sonsini, as well as a number of angel investors including Jeff Dean (Head of Google AI), Uri Lopatin (Khosla, YC, Pardes), Ben Mann (Co-Author GPT-3, Co-Founder Anthropic), Alec Nielsen (CEO Asimov), Trevor Martin (CEO Mammoth), Juan Benet (Founder Filecoin), Nish Bhat (Co-Founder Color Health), Jim Dahl(Rock Creek Capital), and De Thompson V (Legends Capital).
The company intends to use the funds to accelerate the development of treatments targeting proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity.
Led by Armand B. Cognetta III, PhD, Founder and CEO, General Proximity provides a proprietary OmniTAC platform that enables the precise and selective modification of disease-driving proteins, creating therapeutic opportunities for traditionally undruggable targets. The company’s first wave of drug candidates are focused on oncology, cardiometabolic disease, neurodegenerative diseases, and longevity, areas where unmet medical needs are profound.
General Proximity has assembled a Scientific & Strategic Advisory Board featuring key opinion leaders from top biotechnology and pharmaceutical companies such as Martin Babler (Genentech, Principia, Alumis), Lawrence Hamann (Bristol-Myers Squibb, Novartis, Celgene, Takeda, Interdict), and Andy Crew (Astellas, Arvinas, Siduma) alongside a number of academic experts in cancer biology and neurodegeneration.
FinSMEs
06/01/2025